Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.61 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | PTGIR | P43119 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477529 | 0.94 | PTGDR2 (0.62) | PTGDR2PTGDRCYP2C9 | |
| SCHEMBL5438307 | 0.92 | PTGDR2 (0.60) | PTGDR2PTGDRCYP2C9 | |
| SCHEMBL5473428 | 0.92 | PTGDR2 (0.57) | PTGDR2PTGDRCYP2C9 | |
| SCHEMBL5476456 | 0.90 | PTGDR2 (0.72) | PTGDR2PTGDR | |
| SCHEMBL5474079 | 0.90 | PTGDR2 (0.63) | PTGDR2PTGDRCYP2C9 | |
| SCHEMBL5470523 | 0.89 | PTGDR2 (0.60) | PTGDR2PTGDRCYP2C9PTGIR | |
| SCHEMBL5482764 | 0.89 | PTGDR2 (0.59) | PTGDR2PTGDRCYP2C9 | |
| SCHEMBL5479480 | 0.89 | PTGDR2 (0.56) | PTGDR2PTGDRCYP2C9 | |
| SCHEMBL5480500 | 0.86 | PTGDR2 (0.61) | PTGDR2PTGDRCYP2C9 | |
| SCHEMBL5485791 | 0.86 | PTGDR2 (0.55) | PTGDR2PTGDRCYP2C9PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232681-A1 | Compounds Having Crth2 Antagonist Activity | OXAGEN LIMITED (GB) | 2007-10-04 | — | — | US | claimed |
| JP-2007508363-A | — | — | 2007-04-05 | — | — | JP | claimed |
| EP-1675826-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | Oxagen Limited (GB) | 2006-07-05 | — | — | EP | claimed |
| WO-2005040114-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2005-05-06 | — | — | WO | claimed |
| US-20070232681-A1 | Compounds Having Crth2 Antagonist Activity | OXAGEN LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| EP-1675826-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | Oxagen Limited (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005040114-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232681-A1 | Compounds Having Crth2 Antagonist Activity | HRH2, HRH4, HRH3 | PTGDR2 382/4885PTGDR 256/4885CYP2C9 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.